- Syracuse University College of Law, J.D.
- University of Rhode Island, M.S., Microbiology
- University of Rhode Island, B.S., Microbiology
- U.S. District Court, District of Massachusetts
- U.S. Court of Appeals, Federal Circuit
- U.S. Patent and Trademark Office
David is recognized by IAM Patent 1000 as one of the world’s leading patent practitioners. In 2013, David was recognized as an “IP Star” by Managing Intellectual Property. Additionally, he was recognized as a “Life Sciences Star” by LMG Life Sciences in 2012 and 2013. David was also recognized by Super Lawyers in 2013.
David is a member of the Association of University Technology Managers and the American Intellectual Property Law Association. David is also a member of the Personalized Medicine Coalition’s Public Policy Committee.
DAVID S. RESNICK
David Resnick is the co-leader of the Patents practice group at Nixon Peabody. He works with start-up and established companies, as well as major U.S. research institutions, to develop comprehensive patent strategies to protect their intellectual property.
What do you focus on?
My practice is focused on strategic portfolio management, patent prosecution, transactional matters and associated client counseling. I manage the patent portfolios of some of the leading U.S. research institutions and domestic and international corporations. I also represent some of the world’s most recognized life sciences corporations before the U.S. Patent and Trademark Office. I have extensive experience in the life sciences and have particular experience in the areas of pharmacogenomics, proteomics and disease biomarkers and their application in the evolving field of personalized medicine.
I’ve written articles on patent prosecution practice, personalized medicine and technology issues for Nature Biotechnology, The Journal of Biolaw & Business, Personalized Medicine and other publications. I’m also a member of the editorial board of Pharmaceutical Patent Analyst.
Strategic portfolio management
I regularly assist clients in building and evaluating their intellectual property portfolios as well as in evaluating the intellectual property held by competitors. I regularly conduct freedom-to-operate analyses and prepare infringement and validity opinions involving complex and cutting-edge technologies.
I assist clients with patent prosecution in the areas of:
- Molecular biology, genetics, biochemistry and immunology
- Pharmaceuticals, including oncology
- Stem cells/regenerative medicine
- Medical devices
- Microfluidic devices
Transactions and related counseling
I work closely with my clients to identify and analyze acquisition targets and regularly conduct due diligence related to potential acquisitions.
What do you see on the horizon?
In the aftermath of the Prometheus decision, and until such time as further judicial decisions provide greater clarity, I foresee that many life sciences companies will continue to struggle with respect to what qualifies as patent-eligible subject matter.
- Led due diligence on intellectual property matters in connection with a significant investment by a U.S. VC in an international diagnostic/personalized medicine company.
- Provide a broad range of patent services (including patent portfolio management) to a large institute involved in regenerative medicine (stem cells); assist the institute in devising and executing strategies that will extract the greatest value from their IP and also assist them in maneuvering around other people’s patents.
- Helped develop a patent portfolio for an institute of a large research university that is conducting high-stakes research focused on engineering materials and devices with applications in medicine, energy, manufacturing, and the environment; work closely with the client’s inventors on protecting break-through technologies.
- Co-author of a stem cell book chapter in The Delivery of Regenerative Medicines and Their Impact on Healthcare
- “Global Protection of Personalized Medicine Innovation” (D.S. Resnick and L.H. Karttunen Contarino), submitted for publication, 2011
- “U.S. PTO Restriction Practice: Personalized medicine claims with SNPs” (D.S. Resnick, L.H. Karttunen Contarino), June 13, 2011
- “Protecting personalized medicine innovation in China and India: Are diagnostic methods patentable?” (D.S. Resnick, L.H. Karttunen Contarino), May 17, 2011
- “The Federal Circuit reaffirms separate written description and enablement requirements under the patent statute” (D.S. Resnick, R.I. Eisenstein, and M. FitzGerald), March 23, 2010
Recent Speaking Engagements
- “Patent Eligibility of Biomarkers and Diagnostic Methods,” Policy Committee Meeting, Personalized Medicine Coalition (PMC), Washington, DC, December 6, 2011
- “Analyzing and Resolving the Difficulties of Claiming Joint Infringement After Akamai and McKesson,” Practical Strategies for Prosecuting and Litigating Biotech Patents in a Rapidly Shifting Legal Environment, 13th Advanced Forum on Biotech Patents, Boston, MA, December 1, 2011
- Update on U.S. case law and the new Patent Act, 2011 CIPA Life Sciences Conference, The Chartered Institute of Patent Attorneys (CIPA), Warwickshire, United Kingdom, November 17–18, 2011
- “Overview of IP Due Diligence—The Basics,” “Industry-Specific Due Diligence Issues: Life Sciences Industry, Patents Dominant IP,” and “Valuation Issues,” Conducting IP Due Diligence and Ascertaining IP Value, Boston, MA, October 28, 2011
- Myriad Decision Aftershocks Ripple through Biotech
Nature Biotechnology | August 8, 2013
Co-leader of the Patents practice and Life Sciences partner David Resnick discusses the impact of the June 2013 U.S. Supreme Court decision in the Myriad Genetics case.
- SCOTUS: Human Genes Can't Be Patented
CNBC | June 13, 2013
Co-leader of the firm’s Patents practice and member of the Life Sciences team David Resnick discusses the U.S. Supreme Court’s ruling that human genes cannot be patented, striking down Myriad Genetics Inc.'s patents on isolated DNA associated with an increased risk of breast cancer.
- Personalized Medicine Could Hinge on Supreme Court Ruling
BioWorld Today | December 8, 2011
This story notes that the future of personalized medicine rests in the hands of the U.S. Supreme Court as it mulls arguments in Mayo Collaborative Services v. Prometheus Laboratories Inc. Patents practice co-leader and member of the firm’s Life Sciences practice David Resnick provides third-party commentary.